Lori A. Daiello, PharmD, BCPP
President, Pharmacotherapy Solutions
Assistant Professor of Neurology
Warren Alpert Medical School of Brown University
Research Associate, Alzheimer's Disease and Memory Disorders Center
Rhode Island Hospital
Providence, Rhode Island
Gary W. Small, MD
Parlow-Solomon Professor on Aging
Professor of Psychiatry and Biobehavioral Sciences
Director, UCLA Center on Aging
Director, Memory and Aging Research Center
Jane and Terry Semel Institute for Neuroscience & Human Behavior
Los Angeles, California
Pharmacists: 1.5 Contact Hours (0.15 CEUs)
NOTE: This activity was presented on November 18, 2009, in conjunction with ASCP's 40th Annual Meeting and Exhibition.
Participants who received credit for attending either the live presentation or webcast on that date are not eligible to receive credit for this online activity.
The burden of Alzheimer's disease (AD) is well known; in the United States, $148 billion dollars is spent on the care of more than 5 million individuals with AD—a number that is expected to climb to 7.7 million people by the year 2030. It is now the sixth leading cause of death in Americans over the age of 65. While current therapies cannot halt the disease, active medical management can significantly improve the quality of life for patients with Alzheimer's disease and their caregivers.
Although many clinicians are aware of the basic concepts behind the evaluation and management of AD, it is still underrecognized and undertreated. Because pharmacists are accessible, both in the community and in long-term care settings, they are in an ideal position to help identify older adults who require further evaluation. This symposium will discuss strategies to improve the early recognition and treatment of persons with AD and will help pharmacists to determine when and how to add or change therapies to preserve cognitive function, help control behavioral symptoms, and manage common side effects. Faculty also will review advances in clinical research and lifestyle strategies that may diminish memory loss.
. Target Audience
This educational activity is designed for consultant pharmacists who care for older adults with Alzheimer's disease in long-term care settings.
Upon completion of this application-based educational activity, the participant should be able to:
Describe ways to improve the evaluation and management of Alzheimer’s disease in the community and in long-term care settings.
Explain the clinical importance of early identification, evaluation, and treatment for Alzheimer’s disease.
Manage common side effects associated with cholinesterase inhibitors and the NMDA receptor antagonist
Develop individualized treatment plans for patients with varying severity of Alzheimer’s disease.
In accordance with the standards set forth by the Accreditation Council for Pharmacy Education, it is the policy of the American Society of Consultant Pharmacists to ensure balance, independence, objectivity and scientific rigor in all of its educational activities including those which are sponsored and cosponsored. All faculty are expected to disclose any relevant financial relationship or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation. The intent of this disclosure is not to prevent a presenter with a relevant financial relationship or other relationship from making the presentation, but rather to provide the audience with information with which they can make their own judgments. It remains for the audience to determine whether the speaker¹s interests or relationships may influence the presentation with regard to exposition or conclusion. Faculty are also expected to openly disclose any off-label, experimental, or investigational use of drugs or devices in their presentations.
Lori A. Daiello, PharmD, BCPP, discloses that she has served as a consultant for Eli Lilly and Company and as a member of the speakers bureaus for Eli Lilly and Pfizer.
Gary W. Small, MD, discloses that he holds stock or has received honoraria or research funding from the following companies: Abbott, Dakim, Eisai, Forest Laboratories, Medivation, Myriad Genetics, Novartis, Ortho-McNeil, Pfizer, Radica, and Siemens.
This educational activity may contain discussion of published and/or investigational uses of pharmaceutical agents. Some uses of these agents may not have been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Credit Statements
The American Society of Consultant Pharmacists (ASCP) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity, ACPE Universal Activity #203-999-09-069-H01-P, has been assigned 1.5 Contact Hours (0.15 CEUs).
Participants must view the activity in its entirety, successfully complete the post-test, and submit an evaluation to receive continuing pharmacy education credit. Credit will be awarded for a score of 70% or better, and a statement may be printed immediately after passing the post-test.
Partial credit cannot be awarded.
There is no fee to participate in this educational activity.
Commercial Support Statements
This activity is supported through an educational grant from Forest Laboratories, Inc.